Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2017

Planlagt Fastgjort Låst Flyttet Genmab
1.9k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #1125

    😄

    1 Reply Last reply
    0
    • G Offline
      G Offline
      GlobalMacro 0
      wrote on sidst redigeret af
      #1126

      Guys, there was one other important piece of info shared already. Somewhere during the presentation they were talking about dara in smoldring MM and that the data of a phase 2 study is completed, under embargo and presented soon at a big event (ASCO?)

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #1127

        show starting again,

        1 Reply Last reply
        0
        • B Offline
          B Offline
          bibob
          wrote on sidst redigeret af
          #1128

          🙂

          1 Reply Last reply
          0
          • J Offline
            J Offline
            jkj
            wrote on sidst redigeret af
            #1129

            Denne store analyse siger 1,8 mia for dara i usa i 2020http://info.evaluategroup.com/rs/607-YGS-364/images/wp16.pdf

            1 Reply Last reply
            0
            • G Offline
              G Offline
              GlobalMacro 0
              wrote on sidst redigeret af
              #1130

              I think it was during the part where they were explaining their vision relating prevention of disease > smoldring MM

              1 Reply Last reply
              0
              • G Offline
                G Offline
                GlobalMacro 0
                wrote on sidst redigeret af
                #1131

                From live presentation on oncology studies : "move phase 1 studies quick trough registration"!!

                1 Reply Last reply
                0
                • Legolas23L Offline
                  Legolas23L Offline
                  Legolas23
                  wrote on sidst redigeret af
                  #1132

                  Maybe it comes as late breaking at ASCO

                  1 Reply Last reply
                  0
                  • J Offline
                    J Offline
                    JKY_VH
                    wrote on sidst redigeret af
                    #1133

                    https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=318483007&sourcecode=omxnews

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      jkj
                      wrote on sidst redigeret af
                      #1134

                      Konsensus 4.9 mia 2022 side 44http://info.evaluategroup.com/rs/607-YGS-364/images/wp16.pdf

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #1135

                        Or EHA just after ASCO - last year Castor at ASCO and Pollux at EHA

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1136

                          did Lebowitz just say he thinks SubQ could be administered in 5 minutes? Much f
                          aster as i heard before

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #1137

                            Angående konsensus på 2,8 milliarder dollars, så hvis man leger med tanken om Nordea og to andre analytikere, så skal de i gennemsnit ligge på 1,5 milliard - 5,4+1,5+1,5=8,4 og dermed 2,8 i gennemsnit. De 1,5 milliard når vi måske allerede i år. Nordea ligger bestemt i den høje ende, men 2,8 milliard er langt fra sandheden, hvilket bevidner at der må være en del analyser der ikke er opdateret

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #1138

                              Jan all so said 5 minutes in the last CC

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #1139

                                Sleeping analyst they are.

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  saltpeter
                                  wrote on sidst redigeret af
                                  #1140

                                  3 new Phase III studies of daratumumab planned in multiple myeloma and amyloidosis
                                  Studies planned to start between second half 2017 and first quarter 2018
                                  Copenhagen, Denmark; May 17, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its partner Janssen Biotech, Inc. plans to start four new studies of daratumumab in multiple myeloma and amyloidosis. The studies described below are currently planned to start between the second half of 2017 and the first quarter of 2018 and may be

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    saltpeter
                                    wrote on sidst redigeret af
                                    #1141

                                    subject to change. DARZALEX is being developed under an August 2012 agreement in which Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize the product.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      saltpeter
                                      wrote on sidst redigeret af
                                      #1142

                                      Phase III study of daratumumab in smoldering multiple myeloma
                                      Phase III study comparing the subcutaneous and intravenous administration of daratumumab in relapsed and refractory multiple myeloma
                                      Phase III study of daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for amyloidosis
                                      Phase II study of subcutaneous daratumumab in combination with standard of care regimens for frontline and relapsed multiple myeloma

                                      1 Reply Last reply
                                      0
                                      • StockBullS Offline
                                        StockBullS Offline
                                        StockBull
                                        wrote on sidst redigeret af
                                        #1143

                                        Hvis gennemsnit er 2.8 og Nordea har 5.3 saa virker Nordeas kurstarget lavt i forhold til dem som ligger under 5.3

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          JohnW
                                          wrote on sidst redigeret af
                                          #1144

                                          @StockBull, den forstår jeg altså ikke. Kan du uddybe?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger